; and (2) update such list on a schedule determined by the Secretary. (b) Criteria Under subsection (a), a chemotherapeutic drug shall be considered essential for treating pediatric cancer only if the drug— (1) is approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) or licensed under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) for use in the treatment of cancer; (2) has the potential alone or in combination with other drugs to treat a pediatric cancer; (3) is supported by 1 or more citations to treat a pediatric cancer included or approved for inclusion in— (A) the National Comprehensive Cancer Network Compendia; (B) American Hospital Formulary Service Drug Information; (C) the DRUGDEX Information System; or (D) the PDQ Cancer Information Summaries for Health Professionals of the National Cancer Institute